Jpmorgan Chase & CO Arvinas, Inc. Transaction History

Jpmorgan Chase & CO

$1.22 Trillion
Q3 2024

A detailed history of Jpmorgan Chase & CO transactions in Arvinas, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 2,329,303 shares of ARVN stock, worth $43.6 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,329,303

Previous 1,961,960 18.72%

Holding current value

$43.6 Million

Previous $52.2 Million 9.85%

% of portfolio

0.0%

Previous 0.0%

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 08, 2024	BUY	$23.66 - $32.73 $8.69 Million - $12 Million	367,343 Added 18.72%	2,329,303 $57.4 Million
Q2 2024 Aug 12, 2024	BUY	$24.46 - $40.4 $6.41 Million - $10.6 Million	262,117 Added 15.42%	1,961,960 $52.2 Million
Q1 2024 May 10, 2024	SELL	$36.38 - $52.31 $17.2 Million - $24.7 Million	-472,986 Reduced 21.77%	1,699,843 $70.2 Million
Q4 2023 Dec 26, 2024	SELL	$14.19 - $42.33 $2.22 Million - $6.62 Million	-156,474 Reduced 6.72%	2,172,829 $89.4 Million
Q4 2023 Feb 12, 2024	BUY	$14.19 - $42.33 $2.61 Million - $7.77 Million	183,582 Added 9.23%	2,172,829 $89.4 Million
Q3 2023 Nov 14, 2023	SELL	$19.64 - $28.21 $176,288 - $253,212	-8,976 Reduced 0.45%	1,989,247 $39.1 Million
Q2 2023 Aug 11, 2023	SELL	$21.73 - $31.43 $309,000 - $446,934	-14,220 Reduced 0.71%	1,998,223 $49.6 Million
Q1 2023 May 18, 2023	BUY	$26.15 - $37.26 $1.59 Million - $2.27 Million	60,986 Added 3.13%	2,012,443 $55 Million
Q1 2023 May 11, 2023	SELL	$26.15 - $37.26 $411,862 - $586,845	-15,750 Reduced 0.8%	1,951,457 $53.3 Million
Q4 2022 Feb 13, 2023	SELL	$32.47 - $57.24 $4.05 Million - $7.14 Million	-124,803 Reduced 5.97%	1,967,207 $67.3 Million
Q3 2022 Nov 14, 2022	SELL	$41.87 - $57.99 $2.87 Million - $3.98 Million	-68,587 Reduced 3.17%	2,092,010 $93.1 Million
Q2 2022 Aug 11, 2022	BUY	$36.01 - $74.24 $10.1 Million - $20.8 Million	280,691 Added 14.93%	2,160,597 $90.9 Million
Q1 2022 May 11, 2022	SELL	$60.27 - $81.57 $1.39 Million - $1.89 Million	-23,129 Reduced 1.22%	1,879,906 $127 Million
Q4 2021 Feb 10, 2022	BUY	$65.85 - $96.21 $3.09 Million - $4.51 Million	46,895 Added 2.53%	1,903,035 $156 Million
Q3 2021 Nov 12, 2021	BUY	$73.2 - $107.87 $136 Million - $200 Million	1,856,140 New	1,856,140 $153 Million

Others Institutions Holding ARVN

# of Institutions

229

Shares Held

68.4M

Call Options Held

226K

Put Options Held

285K

View Full List

About ARVINAS, INC.

Ticker ARVN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,205,300
Market Cap $997M
Description
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...

More about ARVN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Arvinas, Inc. Transaction History